NEW YORK – GSK will roll out its anti-PD-1 therapy Jemperli (dostarlimab) for certain endometrial cancer patients and its PARP inhibitor Zejula (niraparib) for ovarian cancer patients in India.

Collaborators from various institutions will leverage the latest multi-disciplinary drug development tools to produce tailored treatment and prevention strategies.

A recent paper has shed more light on how corticosteroids frequently prescribed to lung cancer patients could inhibit the ...

The company is testing its lead asset, a CAR T/NK-cell therapy, in a Phase I trial in patients with B-cell malignancies.

A lab's interpretation that an STK11 variant of uncertain significance is likely pathogenic supports a young woman's ...

Researchers led by the nonprofit 4YouandMe and Mount Sinai want to identify second-site suppressor mutations as drug targets ...

NEW YORK – Kelonia Therapeutics this week said it has started treating patients with relapsed and refractory multiple myeloma in a Phase I trial of its in vivo CAR T-cell therapy KLN-1010.

The latest report from the Make-an-IMPACT program focused on results delivered for pediatric cancer patients across 11 ...

NEW YORK – Krystal Biotech has discontinued a Phase I/II clinical trial evaluating an injected version of its gene therapy KB707 in locally advanced or metastatic solid tumors, including melanoma.

The firm will evaluate its EGFR-targeted ADC ALX2004 in advanced non-small cell lung, head and neck, esophageal, and colorectal cancers.

ALX hopes to gain insights by tracking EGFR expression in a new trial of ALX2004 and to identify best responders using CD47 expression in a trial of evorpacept.

The antisense oligonucleotide is a prophylactic treatment for preventing swelling attacks due to hereditary angioedema.